Supplemental Tables from Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth

Supplemental Tables 1-2</p

Supplemental Figures from Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth

Supplemental Figures 1-8</p

Supplementary Information and Figures from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Supplementary Figures, Materials and Methods, and Descriptions of Supplementary files Supplementary Figure 1. Ligand displacement of GC from GR LBD. Supplementary Figure 2. C297 monotherapy is not cytotoxic in vitro or in vivo. Supplementary Figure 3. Mif and C297 antagonize Dex-regulated gene expression in MDA-MB-231 cells. Supplementary Figure 4. Dex-induced genome-wide GR peak locations (ChIP-seq) are lost by the addition of Mif or C297. Supplementary Figure 5. GR antagonists inhibit Dex-induction of canonical GR target genes, and transient knockdown of two additional target genes (MCL1 and NNMT) restores paclitaxel cytotoxicity in the presence of Dex. Supplementary Figure 6. Median and quartile association of NR3C1 expression with RFS in the Validation Cohort. Supplementary Figure 7. The GRsig is not predictive of RFS in ER+ BC patients. Supplementary Figure 8. GRsig expression in PDXs derived from TNBCs from the Mayo Clinic BEAUTY trial.</p

Supplementary File 3 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Graphical images of GR ChIP-seq peaks in regions flanking the TSSs of the n=31 GR putative direct target genes contained in the GRsig</p

Supplementary File 2 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Details about the n=232 putative direct GR targets and Dex GR peaks that are loss, gained, or conserved upon addition of GR antagonists.</p

Supplementary File 1 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Patient and tumor prognostic values of study cohorts and a flow chart of the study design.</p